Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ETS‐targeted therapy: can it substitute for MEK inhibitors?

2 May 2017

Abstract excerpt

BACKGROUND: The RAS/MAPK pathway has been intensively studied in cancer. Constitutive activation of ERK1 and ERK2 is frequently found in cancer cells from a variety of tissues. In clinical practice and clinical trials, small molecules targeting receptor tyrosine kinases or components in the MAPK cascade are used for treatment. MEK1 and MEK2 are ideal targets because these enzymes are physiologically important and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Melanoma and MAPK Pathways
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28474232
DOI: 10.1186/s40169-017-0147-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ETS‐targeted therapy: can it substitute for MEK inhibitors?PMID 28474232Read ↗

Targeting pathological ERK1/2 signaling in cancer and beyondSemantic proximity Read ↗

Novel mitogen-activated protein kinase kinase inhibitors.Semantic proximity Read ↗

RAS/RAF/MEK Inhibitors in OncologySemantic proximity Read ↗

The MEK/ERK Network as a Therapeutic Target in Human CancerSemantic proximity Read ↗

MEK and the inhibitors: from bench to bedsideSemantic proximity Read ↗

Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.Semantic proximity Read ↗

Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancerSemantic proximity Read ↗

Oncogenic signaling of MEK5-ERK5.Semantic proximity Read ↗

ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?Semantic proximity Read ↗

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancerSemantic proximity Read ↗

Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variantsSemantic proximity Read ↗

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.